新产业 (300832)
Shenzhen New Industries Biomedical Engineering Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 78571.88
- Circulating A-Shares(W): 68199.74
- Earnings Per Share(RMB): 1.5334
- Net Assets Per Share(RMB): 11.1297
- Operating Revenue(W RMB): 342761.96
- Total Profit(W RMB): 136664.73
- Net Profit Attributable to Parent(W RMB): 120480.26
- Net Profit Growth Rate(%): -12.92
- Weighted Return on Equity(%): 13.8100
- Operating Cash Flow Per Share(RMB): 1.3540
- Undistributed Profit Per Share(RMB): 7.9002
- Capital Reserve Per Share(RMB): 1.6957
2. Main Business
The main business covers:
- Research, production, sales and customer service of products in the in-vitro diagnostics field
3. Company Basic Information
- Company Name: Shenzhen New Industries Biomedical Engineering Co., Ltd.
- Listing Date: 2020-05-12
- Industry: Pharmaceutical Manufacturing
- Address: New Industries Biomedical Building, No. 23 Jinxiu East Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen City, Guangdong Province
- Website: www.snibe.com
- Company Profile: On November 13, 1995, Shenzhen Fair Accounting Firm verified the capital contribution at the establishment of New Industries Co., Ltd. and issued the "Capital Verification Report" (Shenghuiyanzi [1995] No. 161). On December 15, 1995, New Industries Co., Ltd. obtained the "Business License" issued by the Shenzhen Administration for Industry and Commerce. On August 17, 2012, the company held a shareholders' meeting and passed a resolution to convert the entire company into a joint-stock company based on the audited net asset value of RMB 162,976,369.76 as of May 31, 2012, at a ratio of 1.6298:1. The total share capital of the joint-stock company was 100 million shares, and the portion exceeding the registered capital at the time of conversion, RMB 62,976,369.76, was recorded as capital reserve of the joint-stock company. All shareholders of the company contributed their corresponding share of the net assets of the company's equity at a ratio of 1.6298:1 to become the promoters' shares of the joint-stock company. On August 23, 2012, upon approval by the Shenzhen Market Supervision Administration, the joint-stock company obtained the amended "Business License".
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Tibet New Industries Investment Management Co., Ltd. | General Legal Person | 21117.74 | 30.96 |
| 2 | Tianjin Hongshan Juye Equity Investment Partnership (Limited Partnership) | General Legal Person | 8345.41 | 12.24 |
| 3 | Hong Kong Securities Clearing Company Ltd. | Northbound Funds | 2648.24 | 3.88 |
| 4 | National Social Security Fund 503 Portfolio | Social Security Fund | 1700.01 | 2.49 |
| 5 | HuaBao CSI Medical ETF | Fund | 1109.91 | 1.63 |
| 6 | E Fund Blue Chip Select Hybrid Securities Investment Fund | Fund | 1100.01 | 1.61 |
| 7 | Shanghai Zhancheng Investment Management Co., Ltd. - Zhancheng Darwin Flagship Private Fund | General Legal Person | 868.00 | 1.27 |
| 8 | E Fund ChiNext ETF | Fund | 710.69 | 1.04 |
| 9 | Fullgoal Consumption Theme Hybrid Securities Investment Fund Class A | Fund | 326.21 | 0.48 |
| 10 | Fullgoal Value Creation Hybrid Securities Investment Fund Class A | Fund | 251.99 | 0.37 |
5. Concept Sectors
- Hepatitis Concept
- DeepSeek
- Margin Trading & Securities Lending
- High-Performance Stock
- Social Security Fund Heavy Holdings
- Non-Cyclical Stock
- Zhongchuang 100
- ChiNext Index
- Mid-Cap Growth
- SZSE 100
- SZSE 300
- Technology 100
- Private Enterprise 100
- SZSE Growth
- SZSE Growth Index
- CSI 300
- ChiNext 300
- CSI 200
- CSI 300 Non-Cyclical
- SZSE Innovation
- ChiNext Innovation
- ChiNext Blue Chip
- ChiNext Large Cap
- ChiNext Quality
- ChiNext Technology
- ChiNext Pharmaceutical
- STAR Market and ChiNext 50
- Innovation 100
- CSI 300 ESG
- Pearl River Delta
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information